Paper Details

  1. Home
  2. Paper Details

A study of 656 patients with "early" ovarian cancer.

Author: DavyM L, GuthrieD, PhilipsP R

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 656 patients with epithelial ovarian cancer found that patients with tumors of borderline malignancy or stage Ia(i) well-differentiated tumors did not require adjuvant therapy. Survival was poor for patients with clear cell carcinoma regardless of stage. No significant difference was found between different adjuvant treatments, but patients who received no further treatment after surgery had significantly better survival.
Paper Details　
Original Abstract of the Article :
Six hundred fifty-six patients with epithelial ovarian cancer that had been totally excised macroscopically were analyzed with the intention of providing information for a prospective randomized trial of adjuvant therapy. No deaths occurred in patients with tumors of borderline malignancy or those w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0090-8258(84)90222-1

データ提供：米国国立医学図書館（NLM）

Navigating the Complexities of Early Ovarian Cancer

Ovarian cancer, a serious and often challenging disease, requires careful consideration of treatment options. This study analyzed data from 656 patients with epithelial ovarian cancer that had been surgically removed. The goal of this analysis was to provide valuable insights for designing a prospective randomized trial of adjuvant therapy.

The study found that adjuvant therapy was not justified for patients with tumors of borderline malignancy or those with stage Ia(i) well-differentiated tumors. Interestingly, patients with clear cell carcinoma had a poor survival rate regardless of stage. While no statistically significant difference was found between various modalities of adjuvant treatment, patients who did not receive any further treatment after primary surgery had a significantly better survival rate. This unexpected finding warrants further investigation.

The Importance of 'No Treatment' Groups in Clinical Trials

The study emphasizes the crucial need to include a 'no adjuvant treatment' group in any prospective study of ovarian cancer. This approach allows researchers to better assess the true benefit of various treatment modalities and provides valuable data for guiding clinical decision-making.

A Camel's Perspective: The Crossroads of Ovarian Cancer Treatment

The treatment of ovarian cancer is like a camel crossing a desert – there are many paths to take, and it's essential to choose the one that leads to the best outcome. This study highlights the need for careful analysis and a deep understanding of the complexities of ovarian cancer treatment.

Dr. Camel's Conclusion

This study provides valuable insights into the treatment of early ovarian cancer. It emphasizes the importance of considering the specific characteristics of the tumor, the stage of the disease, and the patient's overall health when making treatment decisions. The study also highlights the crucial need to include 'no treatment' groups in clinical trials to accurately assess the benefits of various treatment modalities.
Date :
  1. Date Completed 1984-05-14
  2. Date Revised 2019-08-25
Further Info :

Pubmed ID

6706234

DOI: Digital Object Identifier

10.1016/0090-8258(84)90222-1

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.